Business Description
Artiva Biotherapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US04317A1079
Description
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.95 | |||||
| Equity-to-Asset | -2.52 | |||||
| Debt-to-Equity | -0.08 | |||||
| Debt-to-EBITDA | -0.54 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | -4.67 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -17.1 | |||||
| 3-Year EPS without NRI Growth Rate | -17.7 | |||||
| 3-Year FCF Growth Rate | -54.2 | |||||
| 3-Year Book Growth Rate | -44.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 33.56 | |||||
| 9-Day RSI | 37.33 | |||||
| 14-Day RSI | 41.36 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.59 | |||||
| Quick Ratio | 4.59 | |||||
| Cash Ratio | 4.3 | |||||
| Days Sales Outstanding | 1174.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -35.5 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -12223.9 | |||||
| Net Margin % | -11354.58 | |||||
| FCF Margin % | -11654.58 | |||||
| ROA % | -31.53 | |||||
| ROIC % | -106.09 | |||||
| ROC (Joel Greenblatt) % | -130.1 | |||||
| ROCE % | -38.71 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 383.01 | |||||
| EV-to-EBIT | -7.94 | |||||
| EV-to-EBITDA | -8.26 | |||||
| EV-to-Revenue | 970.73 | |||||
| EV-to-FCF | -7.65 | |||||
| Earnings Yield (Greenblatt) % | -12.59 | |||||
| FCF Yield % | -10.8 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ARTV
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Artiva Biotherapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.251 | ||
| EPS (TTM) ($) | -5.184 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 41.36 | ||
| 14-Day ATR ($) | 1.543083 | ||
| 20-Day SMA ($) | 14.0445 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 9.71 - 17.31 | ||
| Shares Outstanding (Mil) | 24.29 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Artiva Biotherapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Artiva Biotherapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Artiva Biotherapeutics Inc Frequently Asked Questions
What is Artiva Biotherapeutics Inc(ARTV)'s stock price today?
The current price of ARTV is $11.15. The 52 week high of ARTV is $17.31 and 52 week low is $9.71.
When is next earnings date of Artiva Biotherapeutics Inc(ARTV)?
The next earnings date of Artiva Biotherapeutics Inc(ARTV) is 2024-11-29 Est..
Does Artiva Biotherapeutics Inc(ARTV) pay dividends? If so, how much?
Artiva Biotherapeutics Inc(ARTV) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers